MNTA Schwartz is your man, Wheeler, when you need another equity raise.
Momenta’s technology, developed at Massachusetts Institute of Technology in Cambridge, has proven superior, and the company has a better relationship with the FDA, said Joseph Schwartz, a Leerink Swann & Co. analyst in Boston, in a Jan. 5 note to investors.
“Momenta stands out among the crowd with its follow-on biologics strategy,” Schwartz wrote. “It is in a unique position to corner this market.”
Market Data 
Markets 
AI
